Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Assessment of Gaps in Hematology Education in Canadian Internal Medicine Residency Programs

Danyal Ladha, Kevin Imrie, Christopher J. Patriquin, Liying Zhang

Blood (2023) 142 (Supplement 1): 7192.

https://doi.org/10.1182/blood-2023-191019

Published: 2023

Journal Articles

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Rena Buckstein, Olivia Lopes, Amy J. M. McNaughton, Matthew C. Cheung, Lee Mozessohn, Lisa Chodirker, Kevin Imrie, Neil Berinstein, Signy Chow, Gillian Kupakuwana-Suk, Anne Parmentier, Prasha Sasitharakumar, Hubert Tsui, Liying Zhang, Michael J. Rauh

Blood (2023) 142 (Supplement 1): 442.

https://doi.org/10.1182/blood-2023-187778

Published: 2023

Journal Articles

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Anca Prica, MD FRCP(C), Annette E Hay, Michael Crump, MD, Nicole Mittman, Lois E. Shepherd, Ralph Meyer, MDFRCPC, Kevin Imrie, MD, Nancy A. Risebrough, Marina S Djurfeldt, MSc, Bingshu E. Chen, Matthew Cheung, MD MS, FRCP

Blood (2017) 130 (Supplement 1): 4673.

https://doi.org/10.1182/blood.V130.Suppl_1.4673.4673

Published: 2017

Journal Articles

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Liam Smyth, MD FRCPath, Rena Buckstein, MD FRCPC, Pennell Nancy, BSc, Rashmi Weerasinghe, Matthew Cheung, MD MS, FRCP, Eugenia Piliotis, MD FRCP, MD, Kevin Imrie, MD, David Spaner, MD PhD, Marciano D. Reis, MD, Lisa Chodirker, MD, Zeina Ghorab, Violet ruth,nancy Milliken, Angela Boudreau, RN, BScN, MN, CON(C), Neil Berinstein, MD

Blood (2017) 130 (Supplement 1): 4069.

https://doi.org/10.1182/blood.V130.Suppl_1.4069.4069

Published: 2017

Journal Articles

Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis.

Lisa Hicks, Joseph M. Connors, Joy Mangel, Rena Buckstein, Michael Crump, Heather Leitch, Kevin Imrie, Tracy Nagy, Angela Boudreau, Nancy Pennell, David Spaner, Neil Berinstein

Blood (2006) 108 (11): 3051.

https://doi.org/10.1182/blood.V108.11.3051.3051

Published: 2006

Journal Articles

A Systematic Review and Meta-Analysis of Thalidomide in Patients with Previously Untreated Multiple Myeloma.

Lisa Hicks, Adam Haynes, Donna E. Reece, Irwin Walker, Jordan A. Herst, Kevin Imrie

Blood (2006) 108 (11): 3570.

https://doi.org/10.1182/blood.V108.11.3570.3570

Published: 2006

Journal Articles

The Use of Erythropoietic Agents in Patients with Non-Myeloid Hematological Malignancies.

Nadine Shehata, MD, MSc, Irwin Walker, MD, Ralph Meyer, MD, Adam Haynes, MSc, Kevin Imrie, MD

Blood (2006) 108 (11): 3338.

https://doi.org/10.1182/blood.V108.11.3338.3338

Published: 2006

Journal Articles

Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.

Lisa Hicks, Rena Buckstein, Joy Mangel, Eugenia Piliotis, Kevin Imrie, Matthew C. Cheung, David E. Spaner, Marciano D. Reis, Zeina Ghorab, Violet Milliken, Nancy Pennell, Neil Berinstein

Blood (2006) 108 (11): 3067.

https://doi.org/10.1182/blood.V108.11.3067.3067

Published: 2006

Journal Articles

MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).

Robert E. Marcus, MB, Philippe Solal-Celigny, MD, Kevin Imrie, MD, FRCPC, John V. Catalano, MD, Anna Dmoszynska, MD, PHD, João C. Raposo, MD, Fritz C. Offner, MD, PHD, José Gomez-Codina, MD, PHD

Blood (2006) 108 (11): 481.

https://doi.org/10.1182/blood.V108.11.481.481

Published: 2006

Journal Articles

Mabthera (Rituximab) Plus CVP Chemotherapy for First-Line Treatment of Stage III/IV Follicular Non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-Up.

Philippe Solal-Celigny, MD, Kevin Imrie, MD, Andrew Belch, MD, Katherine Sue Robinson, MD, David Cunningham, Antonio Rueda, MD, John Catalano, MD, Fritz Offner, Jan Walewski, MD, João Raposo, MD, Paul Smith, MSc, Robert Marcus, MD

Blood (2005) 106 (11): 350.

https://doi.org/10.1182/blood.V106.11.350.350

Published: 2005

Journal Articles

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

Robert Marcus, Kevin Imrie, Andrew Belch, David Cunningham, Eduardo Flores, John Catalano, Philippe Solal-Celigny, Fritz Offner, Jan Walewski, Joäo Raposo, Andrew Jack, Paul Smith

Blood (2005) 105 (4): 1417–1423.

https://doi.org/10.1182/blood-2004-08-3175

Published: 2005

Journal Articles

A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma.

Nancy Pennell, M.Sc, Anthony Woods, MD, Rena Buckstein, MD, Kevin Imrie, MD, David Spaner, MD, Marciano Reis, MD, Neil Berinstein, MD

Blood (2004) 104 (11): 5203.

https://doi.org/10.1182/blood.V104.11.5203.5203

Published: 2004

Journal Articles

First Analysis of the Completed Mabthera International (Mint) Trial in Young Patients with Low-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Addition of Rituximab to a CHOP-Like Regimen Significantly Improves Outcome of All Patients with the Identification of a Very Favorable Subgroup with IPI=O and No Bulky Disease.

Michael Pfreundschuh, M.D., Lorenz Truemper, M.D., Devinder Gill, M.D, Anders Osterborg, M.D., Ruth Pettengell, M.D., Marek Trneny, M.D., Kevin Imrie, M.D., Jan Walewski, M.D., Pier-Luigi Zinzani, M.D., Markus Loeffler, M.D.

Blood (2004) 104 (11): 157.

https://doi.org/10.1182/blood.V104.11.157.157

Published: 2004

Journal Articles

High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.

Anthony C. Woods, MD, Rena Buckstein, MD, Joy Mangel, MD, Kevin Imrie, MD, David Spaner, MD, Michael Crump, MD, Nancy Pennell, B.Sc, Angela Boudreau, M.Sc, Marciano Reis, MD, Neil Berinstein, MD

Blood (2004) 104 (11): 914.

https://doi.org/10.1182/blood.V104.11.914.914

Published: 2004

NARROW

Assessment of Gaps in Hematology Education in Canadian Internal Medicine Residency Programs

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis.

A Systematic Review and Meta-Analysis of Thalidomide in Patients with Previously Untreated Multiple Myeloma.

The Use of Erythropoietic Agents in Patients with Non-Myeloid Hematological Malignancies.

Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.

MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).

Mabthera (Rituximab) Plus CVP Chemotherapy for First-Line Treatment of Stage III/IV Follicular Non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-Up.

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma.

High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only